HIV-1 resistance and trend analysis in newly diagnosed patients in Belgium
(2014) Acta Clinica Belgica — Vol. 69, n° 1, p. 1-7 (Jan-Feb) (2014)
Files
acb1.pdf
Restricted Access - Adobe PDF
- 162.36 KB
Details
- Authors
- Abstract
- A total of 1055 nucleotide sequences obtained from HIV patients diagnosed in 2008 and 2009 in Belgium were included in this prevalence study. The study population is a group of patients whose visit was considered by the clinician as the first contact with a Belgian AIDS reference centre or with another clinical centre experienced in HIV care. Prevalences of surveillance drug resistance mutations (SDRM) of 11·7% (47/394) and 11·0% (73/661) were observed in 2008 and 2009, respectively. The highest level of SDRM was observed towards nucleoside reverse transcriptase inhibitors (NRTIs) (7·8%), followed by the non-nucleoside reverse transcriptase inhibitors (NNRTIs) (4·2%) and Protease inhibitors (PIs) (2·3%). A potential clinical impact of the SDRM was demonstrated when using the current first-line therapy. A particularly high prevalence of SDRM was observed among intravenous drug users (IDUs) (29·4%). Reanalysis and comparing the data from previous Belgian studies using similar interpretation algorithms could not reveal a significant trend in SDRM prevalence over the last 5 years.
- Affiliations
Citations
Muyldermans, G., Sasse, A., & AIDS reference laboratories. (2014). HIV-1 resistance and trend analysis in newly diagnosed patients in Belgium. Acta Clinica Belgica, 69(1), 1-7 (Jan-Feb). https://doi.org/10.1179/0001551213Z.0000000001 (Original work published 2014)